Colorectal Cancer Clinical Trials in High Point, NC

Colorectal Cancer Clinical Trials in High Point, NC

View the best 10 colorectal cancer medical studies in High Point, North Carolina. Access promising new therapies by applying to a High Point-based Colorectal Cancer clinical trial.

Trials in High Point, North Carolina

Here are the top 10 medical studies for colorectal cancer in High Point, North Carolina

Image of City of Hope National Medical Center in Duarte, United States.

Sotorasib +1 More

Small Molecule Drug

Recruiting2 awardsPhase 3
This trial is testing two doses of sotorasib combined with panitumumab in patients with a specific type of colorectal cancer that has not responded to other treatments. Sotorasib targets a genetic mutation in the cancer cells, while panitumumab helps the immune system attack the cancer. The goal is to see if this combination can help patients live longer without their cancer getting worse.
Image of South Texas Accelerated Research Therapeutics in San Antonio, United States.

SGN-MesoC2

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial is looking at a new drug called SGN-MesoC2 for treating advanced solid tumors, which are cancers that have grown in one place or spread to other parts of the body. Patients
Image of Atrium Health Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem, United States.

Physical Activity Index Assessment

Behavioural Intervention

Recruiting1 award
"This trial aims to see if using a physical activity index screener, exercise coaching, and self-monitoring can help breast or colon cancer patients increase physical activity and reduce time spent sitting or being inactive."
Image of Community Health Network in Indianapolis, United States.

LY3537982

Small Molecule Inhibitor

Recruiting1 awardPhase 1 & 2
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
Image of Phoenix VA Health Care System, Phoenix, AZ in Phoenix, United States.

Colonoscopy +1 More

Procedure

Recruiting1 award
This trial compares two methods for colorectal cancer screening in people aged 50-75. One method uses a camera to find and remove precancerous growths, while the other checks for hidden blood in stool. The study aims to see which method better reduces cancer deaths over time.
Image of University of North Carolina in Chapel Hill, United States.

Weekly Survey

Recruiting1 award4 criteria
This trial aims to identify cancer patients at risk of delayed treatment, so interventions can be provided to get them treatment faster. 240 colorectal and breast cancer patients will be studied.
Image of Saint Thomas More Church in Chapel Hill, United States.

Colorectal Cancer Educational Videos in Spanish

Recruiting1 award1 criteria
This trial aims to study how to improve the participation of Latinos in cancer clinical trials. They will recruit 60 Spanish-speaking individuals from a church in Chapel Hill. Participants will attend an educational session and watch
Image of USC Norris Comprehensive Cancer Center in Los Angeles, United States.

PC14586 +1 More

Small Molecule

Recruiting1 awardPhase 1 & 2
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Image of Sarah Cannon Research Institute - CO in Denver, United States.

ST316

WNT/β-catenin signaling pathway inhibitor

Recruiting1 awardPhase 1
This trial tests a new cancer drug to find if it's safe, how it works, and if it's effective against advanced solid tumors.
Image of Cancer Specialists of North Florida in Jacksonville, United States.

Sotorasib +1 More

Targeted Therapy

Recruiting2 awardsPhase 3
"This trial aims to see if a new treatment called sotorasib, along with panitumumab and FOLFIRI, can improve the time before the cancer progresses in patients with metast

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.